Biotechnology

New study shows low endotoxin biomaterials improve reliability of 3D in vitro models; Pave the way for reduced animal testing

Wed, 15/03/2023 - 07:30
Irving, United States, 15th March 2023 / Sciad Newswire /
KAUST’s “Dear AI” campaign developed by VMLY&R Dubai

KAUST “Dear AI” campaign targets gender bias in AI, profiles Saudi women in tech

Wed, 08/03/2023 - 07:30
THUWAL, SAUDI ARABIA, March 8th 2023 / Sciad Newswire / King Abdullah University of Science and Technology (KAUST) is launching “Dear AI,” an International Women’

BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead

Mon, 20/02/2023 - 07:00
Taipei, Taiwan, February 20th, 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM

KAUST startup Lihytech raises $6 million to extract lithium from seawater

Thu, 02/02/2023 - 13:15
Thuwal, Saudi Arabia, 2nd February 2023 / 
Norizite spray in bottle and box image

NoriZite™ Nasal Spray blocks infection with Omicron SARS-CoV-2 variant in cell culture

Thu, 15/12/2022 - 09:15
New evidence demonstrates that NoriZite creates a physical barrier to prevent viral infection

BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis

Thu, 08/12/2022 - 07:30
Taipei, Taiwan, 8th December 2022 / Sciad Newswire / BRIM Biotechnology, Inc.

MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease

Tue, 06/12/2022 - 07:30
London, United Kingdom, 6th December 2022 / Sciad Newswire / MultiOmic Health, an artificial intelligence-enabled precisio

BRIM Biotechnology, Inc. raises $20 million in Series E funding round

Thu, 01/12/2022 - 08:30
Taipei, Taiwan, 1st December 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinica
LunaGel X-pure Ultrapure porcine skin image

Gelomics Partners With Rousselot Biomedical to Create the World’s First, Ready-to-Use 3D Cell Culture Kits Based on X-PURE® GelMA

Wed, 16/11/2022 - 07:30
Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the

BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting

Tue, 01/11/2022 - 07:30
Taipei, Taiwan, 1st November 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRI

Pages